Page 2 - தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு ஏற்றுமதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு ஏற்றுமதி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு ஏற்றுமதி Today - Breaking & Trending Today

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval
XPOVIO Net Product Sales of $20.2 Million for Fourth Quarter 2020 and $76.2 Million for the Year 2020; Total Revenues of $35.1 Million for the Fourth Quarter 2020 and $108.1 Million for the Year 2020
Positive CHMP Opinion for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma Issued; European Commission Decision Expected by April 2021
Conference Call Scheduled for Today at 8:30 a.m. ET
News provided by
Share this article
Share this article ....

United States , Michaelg Kauffman , Chen Schor , Selective Inhibitor Of Nuclear Export , Adicet Bio Inc , American Society Of Hematology , Therapeutics Inc , European Union , Karyopharm Selective Inhibitor Of Nuclear Export , Connective Tissue Oncology Society , Committee For Medicinal Products Human Use , National Comprehensive Cancer Network , Information Department , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Progress Towards The International Expansion , Exchange Commission , Prnewswire Karyopharm Therapeutics Inc , Development For Solid Tumors , European Medicines Agency , Antengene Therapeutics , Israeli Ministry Of Health , Chief Executive Officer , Clinical Practice Guidelines , Medicinal Products ,

Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Share this article
Share this article
NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner Promedico Ltd., a member of the Neopharm Group, has received a principal approval letter from the Israeli Ministry of Health, Israel s regulatory agency responsible for the approval of new medicines, granting the approval of XPOVIO® (selinexor) for the treatment of patients with either multiple myeloma or diffuse large B-cell lymphoma (DLBCL). The approved indications for XPOVIO are a) in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and b) for the treatment of adult patients with relapse ....

United States , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Takeda Pharmaceutical Company , European Union , Karyopharm Selective Inhibitor Of Nuclear Export , Promedico Ltd , Information Department , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Exchange Commission , Palestinian Authority , European Medicines Agency , Israeli Ministry Of Health , Neopharm Group , Karyopharm Therapeutics , Israeli Ministry , Medicinal Products , Human Use , Chief Scientific Officer , Selective Inhibitor , Nuclear Export , Marketing Authorization Application , New Drug Application , Medical Information ,

Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
European Commission Decision Anticipated by April 2021
News provided by
Share this article
Share this article
NEWTON, Mass., Jan. 29, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the conditional approval for NEXPOVIO® (selinexor) in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. ....

United States , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , World Health Organization , European Commission , Drug Administration , Takeda Pharmaceutical Company , Exchange Commission , Karyopharm Selective Inhibitor Of Nuclear Export , European Union , European Medicines Agency , Committee For Medicinal Products Human Use , Information Department , Karyopharm Therapeutics , Medicinal Products , Human Use , European Economic Area , Chief Scientific Officer , New England Journal , Independent Review , Multiple Myeloma , Selective Inhibitor , Nuclear Export , Marketing Authorization Application , Medical Information ,

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020
XPOVIO® (selinexor) Unaudited Net Product Sales of between $20.0 Million and $20.5 Million for Fourth Quarter 2020 and between $76.0 Million and $76.5 Million for the Full Year 2020
Commercial Launch of XPOVIO in Expanded Multiple Myeloma Indication Fully Underway
News provided by
Share this article
Share this article
NEWTON, Mass., Jan. 11, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2020 total revenue estimates including net product sales for XPOVIO, the Company s first-in-class, oral Selective Inhi ....

United States , Michaelg Kauffman , Selective Inhibitor Of Nuclear Export , Additional Progress Made Toward International Expansion , Karyopharm Therapeutics Inc , Drug Administration , Takeda Pharmaceutical Company , Prnewswire Karyopharm Therapeutics Inc , Exchange Commission , Therapeutics Inc , European Union , Karyopharm Selective Inhibitor Of Nuclear Export , European Medicines Agency , Antengene Therapeutics , Committee For Medicinal Products Human Use , Information Department , Selective Inhibitor , Nuclear Export , Healthcare Conference , Chief Executive Officer , Antengene Therapeutics Limited , South Korea , Marketing Authorization Application , Medicinal Products , Human Use , New Drug Application ,

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

December 21, 2020
Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population -
Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly Bortezomib Combination Regimen -
First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 -
FDA Approval Comes Approximately Three Months Ahead of Target PDUFA Date -
SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc. (Nasdaq: KPTI) for oral XPOVIO ....

United States , Jay Mei , Asia Pacific , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , Antengene Corporation , Drug Administration , Australian Therapeutic Goods Administration , Approval Program , Health Sciences Authority , European Medicines Agency , Antengene Corporation Limited , National Medical Products Administration , National Comprehensive Cancer Network , Combination Therapy , Addressable Patient Population , Only Approved Multiple Myeloma Drug Indicated , Once Weekly Bortezomib Combination Regimen , Multiple Myeloma Drug , New Mechanism , Action Approved , Second Line Setting Since , Comes Approximately Three Months Ahead , New Drug Application , Karyopharm Therapeutics , Selective Inhibitor ,